MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers
Authors:
- Andrea PadoanAndrea Padoan
- Daniela BassoDaniela Basso
- Carlo-Federico ZambonCZCarlo-Federico Zambon
- Tommaso Prayer-GalettiTPTommaso Prayer-Galetti
- Giorgio ArrigoniGAGiorgio Arrigoni
- Dania BozzatoDBDania Bozzato
- Stefania MozSMStefania Moz
- Filiberto ZattoniFZFiliberto Zattoni
- Rino BelloccoRBRino Bellocco
- Mario PlebaniMario Plebani
Open Access
- 25 July 2018
- journal article
- research article
- Published by Springer Nature in Clinical Proteomics
- Vol. 15 (1) , 1-15
Abstract
Lower urinary tract symptoms (LUTS) and prostate specific antigen-based parameters seem to have only a limited utility for the differential diagnosis of prostate cancer (PCa). MALDI-TOF/MS peptidomic profiling could be a useful diagnostic tool for biomarker discovery, although reproducibility issues have limited its applicability until now. The current study aimed to evaluate a new MALDI-TOF/MS candidate biomarker. Within- and between-subject variability of MALDI-TOF/MS-based peptidomic urine and serum analyses were evaluated in 20 and 15 healthy donors, respectively. Normalizations and approaches for accounting below limit of detection (LOD) values were utilized to enhance reproducibility, while Monte Carlo experiments were performed to verify whether measurement error can be dealt with LOD data. Post-prostatic massage urine and serum samples from 148 LUTS patients were analysed using MALDI-TOF/MS. Regression-calibration and simulation and extrapolation methods were used to derive the unbiased association between peptidomic features and PCa. Although the median normalized peptidomic variability was 24.9%, the within- and between-subject variability showed that median normalization, LOD adjustment, and log2 data transformation were the best combination in terms of reliability; in measurement error conditions, intraclass correlation coefficient was a reliable estimate when the LOD/2 was substituted for below LOD values. In the patients studied, 43 peptides were shared by the urine and serum, and several features were found to be associated with PCa. Only few serum features, however, show statistical significance after the multiple testing procedures were completed. Two serum fragmentation patterns corresponded to the complement C4-A. MALDI-TOF/MS serum peptidome profiling was more efficacious with respect to post-prostatic massage urine analysis in discriminating PCa.Keywords
This publication has 29 references indexed in Scilit:
- Prostate cancer proteomics: Current trends and future perspectives for biomarker discoveryOncotarget, 2017
- EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic ObstructionEuropean Urology, 2015
- Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate BiopsyJournal of Urology, 2014
- Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian menWorld Journal of Urology, 2010
- Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profilesJournal of Pharmaceutical and Biomedical Analysis, 2010
- Standardized Peptidome Profiling of Human Urine by Magnetic Bead Separation and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass SpectrometryClinical Chemistry, 2007
- Quantitative PSA mRNA determination in blood: A biochemical tool for scoring localized prostate cancerClinical Biochemistry, 2006
- Influences of Blood Sample Processing on Low–Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass SpectrometryClinical Chemistry, 2005
- Bias as a threat to the validity of cancer molecular-marker researchNature Reviews Cancer, 2005
- Benign Prostatic Hyperplasia and Prostate CancerEpidemiologic Reviews, 2001